TIDMFUM
RNS Number : 6410D
Futura Medical PLC
22 June 2023
22 June 2023
Futura Medical plc
("Futura" or the "Company")
Futura Medical Announces Annual General Meeting Results
Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), a
pharmaceutical company developing a portfolio of innovative
products based on its proprietary, transdermal DermaSys(R) drug
delivery technology currently focused on sexual health, today
announces that at its Annual General Meeting, held today at 10:00am
BST, the shareholders duly passed all resolutions.
The total number of votes received on each resolution were as
follows:
Voting For Voting Against
------------------------------------ ------------------------------------
Number % Number % Total % Votes
of votes(i) of votes Votes ISC withheld(ii)
------------ ---------------------- ------------- ------- ---------- ------ ----------- ------- --------------
To receive
and adopt
the annual
report of
the directors
and the financial
statements
for the financial
year ended
31 December
2022 and
the report
of the appointed
Resolution auditors
1 thereon. 69,770,830 99.98% 11,289 0.02% 69,782,119 24.22% 19,089
---------------------- ------------- ------- ---------- ------ ----------- ------- --------------
To re-elect
John Clarke
as a Director
of the Company,
who retires
by rotation
in accordance
with the
Company's
Resolution articles
2 of association. 69,751,950 99.96% 26,170 0.04% 69,778,120 24.22% 23,089
---------------------- ------------- ------- ---------- ------ ----------- ------- --------------
To re-appoint
Grant Thornton
UK LLP as
auditor of
the Company
to hold office
until the
conclusion
of
the next
annual general
Resolution meeting of
3 the Company. 69,717,388 99.91% 64,733 0.09% 69,782,121 24.22% 19,089
---------------------- ------------- ------- ---------- ------ ----------- ------- --------------
To authorise
the Directors
to determine
the remuneration
of Grant
Thornton
UK LLP as
auditor of
Resolution the
4 Company. 69,720,243 99.91% 61,879 0.09% 69,782,122 24.22% 19,089
---------------------- ------------- ------- ---------- ------ ----------- ------- --------------
To authorise
that the
Directors
of the Company
are generally
and unconditionally
authorised
for the purposes
of section
551
Companies
Act 2006
(the "CA
2006") to
exercise
all the powers
of the Company
to allot
shares in
the
Company and
to grant
rights to
subscribe
for or to
convert any
security
Resolution into shares
5 in the Company 69,231,840 99.87% 90,153 0.13% 69,321,993 24.06% 479,219
---------------------- ------------- ------- ---------- ------ ----------- ------- --------------
A Special
Resolution,
subject to
the passing
of Resolution
5 set out
above, that
authorises
the Directors
to allot
equity
securities
(as defined
in the CA
2006) for
cash under
the authority
given by
that resolution
and/or to
sell ordinary
shares held
by the Company
as treasury
shares for
cash as if
section 561
of the CA
2006
did not apply
to any such
allotment
or sale,
Resolution to be limited
6 (iii) to GBP57,626 69,019,760 99.59% 287,234 0.41% 69,306,994 24.05% 494,219
---------------------- ------------- ------- ---------- ------ ----------- ------- --------------
A Special
Resolution,
subject to
the passing
of Resolution
6 set out
above, that
authorises
the Directors,
in
addition
to any authority
granted under
Resolution
6, to allot
equity securities
(as defined
in the CA
2006) for
cash under
the authority
given by
that resolution
and/or to
sell ordinary
shares held
by the
Company as
treasury
shares for
cash as if
section 561
of the CA
2006 did
not apply
to any such
allotment
or sale,
limited to
GBP57,626,
with such
authority
to be used
only for
Resolution the purposes
7 of financing 69,019,007 99.57% 298,988 0.43% 69,317,995 24.06% 483,219
---------------------- ------------- ------- ---------- ------ ----------- ------- --------------
Where shareholders appointed the Chairman as their proxy with
discretion as to voting, their votes were cast in favour of the
resolution
A vote withheld is not a vote in law and is not counted towards
the votes cast "For" or "Against" a resolution
Special Resolution (75% majority required)
The total voting rights of the Company as at 10:00 am on 22 June
2023 (the time by which shareholders wanting to vote at the AGM
were required to be entered on the register) was 288,133,957
ordinary shares of 0.2p each. The Company does not hold any shares
in treasury
-S-
For further information, please contact:
Futura Medical plc
James Barder, Chief Executive Officer
Angela Hildreth, Finance Director and COO
Email: investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
www.futuramedical.com
Nominated Adviser and Sole Broker:
Liberum
Phil Walker/ Richard Lindley/ Ben Cryer
Tel: +44 (0) 20 3100 2000
For media enquiries please contact:
Optimum Strategic Communications
Hollie Vile/ Jonathan Edwards/ Zoe Bolt
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 882 9621
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company
developing a portfolio of innovative products based on its
proprietary, transdermal DermaSys(R) technology. Each DermaSys(R)
formulation is separately patented and specifically tailored for
the selected indication and application, as well as being optimised
for clinical efficacy, safety, administration and patient
convenience. The products are developed for the prescription and
consumer healthcare markets as appropriate. Development and
commercialisation strategies are designed to maximise product
differentiation and value creation whilst minimising risk.
MED3000 is Futura's topical gel formulation that is a novel
treatment for erectile dysfunction (ED) through a unique
evaporative mode of action. Futura has conducted two Phase 3
studies using MED3000 in ED; FM57 study which enabled Futura to be
granted a CE Mark in 2021 and FM71 which enabled Futura to be
granted US marketing authorisation. Both studies demonstrated that
MED3000 presents an effective clinically proven treatment for ED
with a rapid speed of onset and a favourable benefit versus risk
profile ideally suited for an 'Over the Counter'
classification.
Eroxon(R) is FDA approved in the US, CE marked in Europe and
UKCA marked in the UK as a clinically proven topical treatment for
adult men with erectile dysfunction under the brand Eroxon(R) with
a key claim of "Helps you get an erection within 10 minutes".
Eroxon(R) is the agreed brand name in certain regions such as the
EU whereas MED3000 continues to be the internal code name used by
the Company and also in reference to countries where regulatory
approval or commercial distribution agreements have not yet been
achieved. www.eroxon.com
Futura is based in Guildford, Surrey, and its shares trade on
the AIM market of the London Stock Exchange. www.futuramedical.com
.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGSEMFLEEDSEFM
(END) Dow Jones Newswires
June 22, 2023 10:19 ET (14:19 GMT)
Grafico Azioni Futura Medical (LSE:FUM)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Futura Medical (LSE:FUM)
Storico
Da Mag 2023 a Mag 2024
